Bayer AG released a definitive, legally non-binding statement addressing ongoing regulatory evaluations regarding its corporate portfolio and market positioning, according to an official company announcement published on bayer.com.
Jurisdictional Restrictions and Securities Compliance
The documentation issued by Bayer AG explicitly restricts distribution in the United States, Australia, Canada, and Japan, according to the official corporate statement. Securities mentioned in the regulatory filings have not been, and will not be, registered under the United States Securities Act of 1933. Consequently, these instruments cannot be offered or sold within the United States absent registration or an applicable exemption from registration requirements. Bayer AG confirmed that no public offering of securities will take place in the United States.
Distribution Standards Within the United Kingdom and EEA
Within the United Kingdom, the released materials are directed exclusively at qualified professionals, according to the company’s regulatory disclosures. This includes investment professionals falling under Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as well as high-net-worth entities and unincorporated associations specified under Article 49(2)(a) through (d) of the order. The securities remain accessible solely to these designated persons, and any related investment activity will be engaged in exclusively with them.
For member states of the European Economic Area that have implemented Directive 2003/71/EC, known as the Prospectus Directive, public offerings are restricted unless specific exemptions apply. According to Bayer AG’s documentation, allowable exemptions include offers made to qualified investors, offers directed to fewer than 150 natural or legal persons per member state, or transactions otherwise exempt under Article 3 Paragraph 2 of the Prospectus Directive.
Worth a look